1. Introduction {#sec1}
===============

Coronavirus disease 2019 (COVID-19) was declared pandemic, and at the time this paper was written, it has infected more than 4.7 million people and caused more than 300.000 deaths \[[@bib1]\]. Even though most of the infected patients have mild or no symptoms, some of them develop severe pneumonia, acute respiratory distress syndrome, multi-organ failure, and death. Factors such as age, smoking, diabetes, hypertension, and cardiovascular diseases are associated with severity and mortality in patients with COVID-19 \[[@bib2], [@bib3], [@bib4], [@bib5], [@bib6]\]. Previously, influenza epidemics have been shown to be associated with an increased risk of ventricular arrhythmia in patients with implantable cardiac defibrillators \[[@bib7]\], indicating that respiratory-borne infections might also be related to cardiovascular manifestations.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been shown to cause cardiac injury and cytokine storm, which may lead to cardiac arrhythmias \[[@bib8],[@bib9]\]. A study has shown that cardiac arrhythmias may occur in up to 44% of patients with severe COVID-19 \[[@bib10]\], and has been associated with an increased risk of death \[[@bib11]\]. This systematic review and meta-analysis aimed to evaluate the incidence of cardiac arrhythmias in patients with COVID-19 and their implications on patient prognosis.

2. Methods {#sec2}
==========

2.1. Eligibility criteria {#sec2.1}
-------------------------

This systematic review and meta-analysis included research articles on adult COVID-19 patients that contain information on arrhythmia as a complication and contain a clinically validated definition of severe COVID-19, death, or intensive care unit (ICU) care. We excluded articles other than original research articles (e.g., review articles, non-research letters, or editorial/commentaries), studies with a sample of less than 20 or case reports, non-English language articles, and pediatric populations (age of 17 years old or younger).

2.2. Search strategy and study selection {#sec2.2}
----------------------------------------

We systematically searched PubMed, SCOPUS, Europe PMC, Cochrane Central Databases, and Google Scholar + Preprint Servers with the search terms 1) "COVID-19″ OR "SARS-CoV-2″ AND "Characteristics" 2) "COVID-19″ OR "SARS-CoV-2″ AND "Arrhythmia". Duplicate results were removed. The remaining articles were independently screened by two authors (I. H. and R. P.) for the relevance of their abstracts. The full text of the remaining articles was assessed applying the inclusion and exclusion criteria. The search was finalized on April 14, 2020. The study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

2.3. Data extraction {#sec2.3}
--------------------

Data extraction was performed independently by two of the authors (I. H. and R. P.). We used standardized extraction forms that included author, year, study design, age, sex, cardiovascular diseases, history of hypertension and diabetes mellitus, respiratory comorbidities, antibiotics and antiviral use, glucocorticoid use, lymphopenia, follow-up duration, arrhythmia, mortality, ICU care, and severe COVID-19. The quality and risk of bias assessment of the included studies will be performed using the Newcastle-Ottawa Scale.

The primary endpoint of the study was poor outcome, including mortality, severe COVID-19, and the need for ICU care. Severe COVID-19 was defined as patients who had any of the following features at the time of admission or after admission: (1) respiratory distress (≥30 breaths per min); (2) oxygen saturation at rest ≤ 93%; (3) ratio of partial pressure of arterial oxygen (PaO~2~) to fractional concentration of oxygen inspired air (fiO~2~) ≤ 300 mmHg; or (4) critical complication (respiratory failure, septic shock, and multiple organ dysfunction/failure) \[[@bib12]\].

2.4. Statistical analysis {#sec2.4}
-------------------------

The meta-analysis of the included studies was performed using STATA 16.0 (StataCorp LLC, Texas, US). Meta-analysis of proportions was used to pool the incidence of arrhythmia in the groups. Dichotomous variables were calculated to obtain risk ratios (RRs) along with their 95% confidence intervals (CIs). Random effect models were used regardless of heterogeneity. The p-values were two-tailed and statistical significance was set at ≤ 0.05. A sensitivity analysis by leave-one-out was performed to test the robustness of the findings. To assess the small-study effect, we performed a regression-based Egger's test. Random-effects meta-regression was performed for gender, hypertension, diabetes, cardiovascular diseases, cerebrovascular diseases, respiratory comorbidities, and lymphopenia.

3. Results {#sec3}
==========

3.1. Study selection {#sec3.1}
--------------------

We found 817 records and 509 remained after the removal of duplicates. A total of 461 records were excluded after screening the titles and abstracts. After assessing 48 articles for eligibility, we excluded 44 because of the following conditions: 1) there were no data on arrhythmia as complication (n = 43), and 2) arrhythmia was the baseline comorbidity, not an outcome (n = 1). As a result, 4 studies remained for qualitative synthesis and meta-analysis ([Fig. 1](#fig1){ref-type="fig"} ). There were 784 patients from the 4 studies \[[@bib10],[@bib11],[@bib13],[@bib14]\].Fig. 1Prisma flowchart.Fig. 1

3.2. Baseline characteristics {#sec3.2}
-----------------------------

Baseline characteristics is displayed in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"} . Meta-analysis of baseline characteristics showed that male (RR 1.28 \[1.06, 1.56\], p = 0.01; I^2^: 49%, p = 0.12), hypertension (RR 2.38 \[1.61, 3.51\], p \< 0.001; I^2^: 69%, p = 0.02), diabetes (RR 2.60 \[1.47, 4.61\], p = 0.001; I^2^: 45%, p = 0.14), cardiovascular diseases (RR 3.51 \[2.28, 5.42\], p \< 0.001; I^2^: 0%, p = 0.55), and respiratory comorbidities (RR 4.90 \[2.12, 11.29\], p \< 0.001; I^2^: 0%, p = 0.75) were associated with poor outcome in this pooled analysis. Cerebrovascular diseases (RR 3.78 \[0.72, 19.88\], p = 0.12; I^2^: 81%, p = 0.001) was not associated with poor outcome.Table 1Characteristics of the included studies. Data in the table were arranged as total patients/prevalence (poor outcome group vs. without poor outcome group).Table 1AuthorsStudy DesignSamplesOverall Age (Mean/Median) (years)Male (%)Hypertension (%)Cardiovascular Comorbidities (%)Diabetes (%)Respiratory Comorbidities (%)Hs-troponin I on AdmissionCao J 2020Observational Retrospective102 (17/85)54 (72 vs. 53)52 (76.5 vs. 47.1)27.5 (64.7 vs. 20)4.9 (17.6 vs. 2.4)10.8 (35.3 vs. 5.9)9.8 (23.5 vs. 7.1)7.6 (Overall)Hu L 2020Observational Retrospective323 (172/151)61 (65 vs. 56)51.4 (52.9 vs. 49.7)32.5 (38.3 vs. 25.8)12.7 (19.2 vs. 5.3)14.6 (19.2 vs. 9.3)1.9 (3.5 vs. 0)Mean/Median was not reportedZhang Guqin 2020Observational Retrospective221 (55/166)55 (62 vs. 51)48.9 (63.6 vs. 44.0)24.4 (47.3 vs. 16.9)10 (23.6 vs. 5.4)10 (12.7 vs. 9.0)2.7 (7.3 vs. 1.2)Mean/Median was not reportedWang Dawei 2020Observational Retrospective138 (36 vs. 102)56 (66 vs. 51)54.3 (61.1 vs. 52.0)31.2 (58.3 vs. 21.6)14.5 (25 vs. 10.8)10.1 (22.2 vs. 5.9)2.9 (8.3 vs. 1.0)6.4 (11 vs. 5.1)Table 2Characteristics of the included studies. Data in the table were arranged as total patients/prevalence (poor outcome group vs. without poor outcome group).Table 2AuthorsOutcomeNOSMean Follow-up DurationAntiviral Use (%)Antibiotics Use (%)Glucocorticoid Use (%)Cao J 2020Mortality728 days\
Mean Duration: Not Reported\
Sample: January 3, 2020 to February 15, 2020\
Followed up to: February 15, 2020100 vs 97.6\
Arbidol: 5.9 vs. 37.6\
Oseltamivir: 82.4 vs. 61.2\
Lopinavir + Ritonavir: 23.5 vs. 28.2100 vs. 98.8Methylprednisolone: 64.7 vs 47.1Hu L 2020Severe COVID-19728 days\
Mean Duration: Not Reported\
Sample: January 8, 2020 to February 20, 2020\
Followed up to: March 10, 2020Oseltamivir: 67.4 vs 72.2\
Ganciclovir: 68.0 vs 74.8\
Arbidol: 63.4 vs 65.6\
Kaletra: 13.4 vs 3.3\
Interferon-alpha: 8.1 vs 5.393.6 vs. 94.763.4 vs. 57.6Zhang Guqin 2020Severe COVID-197Mean Duration: Not Reported\
Sample: January 2, 2020 to February 10, 2020\
Followed up to: February 15, 202090.9 vs 88Not Reported72.7 vs 45.2Wang Dawei 2020Intensive Care Unit7Mean Duration: Not Reported\
Sample: January 1, 2020 to January 28, 2020\
Followed up to: February 3, 202090 (Overall)100 (Overall)Methylprednisolone: 45 (Overall)[^1]

3.3. Arrhythmia incidence {#sec3.3}
-------------------------

The incidence of arrhythmia in patients with COVID-19 was 19% (9--28%; I^2^: 91.45, p \< 0.001) ([Fig. 2](#fig2){ref-type="fig"} A). Arrhythmia occurred in 48% (38--57%; I^2^: 48.08, p = 0.12) of patients with poor outcome ([Figs. 2](#fig2){ref-type="fig"}B) and 6% (1--12%; I^2^: 85.33%) of patients without poor outcome ([Fig. 2](#fig2){ref-type="fig"}C).Fig. 2Incidence of arrhythmia in COVID-19 patients with COVID 19. The incidence of arrhythmia is 19% (A). Arrhythmia occurs in 48% (B) of the patients with poor outcomes and 6% (C) of the patients without poor outcomes.Fig. 2

3.4. Arrhythmia and outcome of the COVID-19 {#sec3.4}
-------------------------------------------

Patients with COVID-19 experiencing arrhythmia had an increased risk of poor outcome (RR 7.96 \[3.77, 16.81\], p \< 0.001; I^2^: 71.1%, p = 0.02) ([Fig. 3](#fig3){ref-type="fig"} ). Sensitivity analysis removing the study of Zhang Guqin et al. showed the statistical robustness of the effect estimate (RR 5.83 \[3.26, 10.42\], p \< 0.001; I^2^: 54%, p = 0.11).Fig. 3Arrhythmia and outcome of COVID-19. Patients with COVID-19 experiencing arrhythmia have an increased risk of poor outcome.Fig. 3

3.5. Meta-regression {#sec3.5}
--------------------

The association between arrhythmia and outcome in patients with COVID-19 did not vary significantly with age (p = 0.840), male (p = 0.220), hypertension (p = 0.977), cardiovascular diseases (p = 0.848), diabetes (p = 0.139), respiratory comorbidities (p = 0.729), and lymphopenia (p = 0.084).

3.6. Publication bias {#sec3.6}
---------------------

The funnel-plot analysis showed an asymmetrical funnel plot with most of the studies on the right side of the effect estimate ([Fig. 4](#fig4){ref-type="fig"} ). Regression-based Egger's test showed indication of small-study effects (p = 0.001).Fig. 4Publication bias. The funnel-plot analysis shows an asymmetrical funnel plot with most of the studies on the right side of the effect estimate.Fig. 4

4. Discussion {#sec4}
=============

This meta-analysis showed that the incidence of arrhythmia was significantly higher in patients with poor outcomes, hence a marker of poor prognosis.

Cardiac arrhythmias occurred frequently in patients with COVID-19, and the percentage was even higher in those with poor outcomes. However, this topic remains to be explored and currently, the included studies did not specify the types of arrhythmia. Hence, the specific types of arrhythmia that increase mortality and severity of COVID-19 remain inconclusive.

Defining the types of arrhythmia in patients with COVID-19 is important because of the frequent incidence and is strongly associated with poor prognosis. Providing details on the type of arrhythmia may help clinicians to discriminate the prognostic significance of the arrhythmia, allowing more precise risk stratification. Several baseline characteristics are also associated with poor outcome in this pooled studies. These factors include gender, hypertension, diabetes, cardiovascular diseases, and respiratory comorbidities which is accordance to our previous meta-analyses assessing these factors \[[@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib39]\]. We performed meta-regression and found that the association between arrhythmia and poor outcome did not varied with the gender and other comorbidities, nevertheless the number of studies \<10.

Arrhythmia may be attributed to metabolic disarray, hypoxia, inflammation, or neurohormonal stress associated with SARS-CoV-2 infection \[[@bib15]\]. Furthermore, COVID-19 induced coagulopathy may cause thrombosis leading to hypoxia \[[@bib16],[@bib17]\]. Additionally, which patients often present electrolyte abnormalities that may precipitate/exacerbate cardiac arrhythmias \[[@bib18]\]. SARS-CoV-2 itself has been shown to cause cardiac injury signified by increase in cardiac biomarkers \[[@bib19],[@bib20]\]. After activation of the viral surface spike (S) protein of SARS-CoV-2 by the transmembrane protease serine 2 (TMPRSS2), the virus binds to angiotensin-converting enzyme 2 (ACE2) \[[@bib21],[@bib22]\], which has high affinity to the human receptor \[[@bib23],[@bib24]\]. The aforementioned enzyme is highly expressed in cardiac pericytes \[[@bib25]\], infection, and subsequent immune response may cause damage to the heart. Myocardial inflammation, ion channel dysfunction, electrophysiological and structural remodeling associated with viral myocarditis has been shown to cause life-threatening arrhythmias \[[@bib26]\]. Evidence shows that the rise of troponin is accompanied by increased inflammatory biomarkers, indicating the possible role of cytokine storm in cardiac injury \[[@bib27]\]. Systemic inflammation has been shown to prolong ventricular action potential duration through disturbance of the potassium channel \[[@bib28]\]. Interleukin-6, tumor necrosis factor alpha, and interleukin-1 may prolong the action potential duration through interplay with cardiomyocytes ion channels \[[@bib29]\]. Elevated interleukin-6 during systemic inflammation may cause QT prolongation, which increases the risk for torsades de pointes \[[@bib30]\].

Furthermore, QT-prolonging drugs are frequently used in the management of COVID-19, synergistically amplifying the risk of cardiac arrhythmias. Drugs such as azithromycin and hydroxychloroquine are associated with QT prolongation \[[@bib31],[@bib32]\]. Azithromycin is known to prolong the QT interval \[[@bib33]\] and increase the risk of cardiovascular death \[[@bib34]\]. The anti-malarial chloroquine is associated with prolonged QT interval with or without azithryomycin according to a randomized controlled trial from the Pfizer Labs \[[@bib35]\]. Moreover, lopinavir-ritonavir, a combination of drugs commonly known as protease inhibitors (PI) and usually used as 2nd-line drugs in treating HIV infection, is also recognized as arrhythmogenic and can prolong the QT interval \[[@bib36],[@bib37]\]. Interestingly, Hu et al. reported that these drugs are associated with severe COVID-19, thus potentially affecting the association between arrhythmia and severe COVID-19 \[[@bib14]\]. A risk score developed by Tisdale et al. may be used to predict patients at risk for QTc interval prolongation \[[@bib38]\]. This score may be used to guide treatment choices for patients with COVID-19.

4.1. Limitations {#sec4.1}
----------------

This systematic review and meta-analysis has several limitations. First, the types of cardiac arrhythmias were not described in the included studies. Second, the risk of publication bias was high, as indicated by the asymmetrical funnel plot analysis and statistically significant Egger's test. Third, most of the studies are from China and may not be generalizable to other populations. Fourth, the number of studies were limited and not divided into arrhythmias versus non-arrhythmias; hence, we were not able to assess the risk factors for cardiac arrhythmias in these patients. Fifth, the studies did not report the level of electrolytes. Sixth, the studies were mostly retrospective. The predictive power of meta-regression analysis is weaker if the number of studies are \<10. Nevertheless, this study emphasizes the clinical importance of arrhythmia in patients with COVID-19, and further studies should explore cardiac arrhythmias in these patients.

5. Conclusion {#sec5}
=============

Cardiac arrhythmias were significantly associated with an increased risk of poor outcome in COVID-19. Arrhythmias were observed in 19% of patients with COVID-19 and in 48% of patients with poor outcomes.
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[^1]: NOS: Newcastle-Ottawa Scale.
